Search Results
Jul 31, 2026, 08:51 ET Leica Store and Gallery Boston Celebrates 10 Years with Community Garden
McClure, Phil Penman, Maggie Steber, Alex Webb, Rebecca Norris Webb, and Eva Woolridge.The exhibition also welcomes four emerging photographers: Mav Fernandez, Raphael Lehnen, Artemisia Luk, and Abdoul Nasser Mika. Together, these artists reflect the evolving creative energy of Boston's photographic
More news about: Leica Camera USA
Jul 27, 2026, 09:00 ET Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Lead D-MAV demonstrates cross-viral family fusion inhibition, validating theplatform; opens a new program in filovirus pandemic preparednessCAMBRIDGE, Mass., July 27, 2026 /PRNewswire/
More news about: Decoy Therapeutics, Inc
Jul 15, 2026, 09:24 ET Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors
sure important medicines reach the people who need them, at scale and in the real world. We're glad to welcome her to the Board as we advance our D-MAV programs toward the clinic," said Rick Pierce, Chief Executive Officer of Decoy Therapeutics. "Her experience building commercial organizations and delivering
More news about: Decoy Therapeutics, Inc
Jun 11, 2026, 04:00 ET Climate Impact Partners secures a historic one million tonne carbon removals purchase from GreenTrees' Mississippi Alluvial Valley ARR Project
GreenTrees' Mississippi Alluvial Valley (MAV) Reforestation Project is reforesting land long exhausted by intensive agriculture. To date it has:- Removed nearly 8 million
More news about: ACRE Investment Management; Climate Impact Partners (CIP)
Jun 03, 2026, 08:00 ET Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
"Patricia has spent her career making sure important medicines reach the people who need them, at scale and in the real world. As we advance our D-MAV programs toward the clinic, her experience building commercial organizations, securing national health security partnerships and delivering medicines
More news about: Decoy Therapeutics, Inc
Jun 01, 2026, 07:00 ET Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
preparation for Decoy's lead D-MAV candidate. The outputs will serve as a future rapid preclinical and clinical template for Decoy's growing portfolio of D-MAV drug candidates. Decoy believes its platform architecture may allow for similar clinical trial designs across multiple D-MAV candidates, subject to regulatory
More news about: Decoy Therapeutics, Inc
May 06, 2026, 07:47 ET Paessler Appoints Mav Turner as Chief Product Officer to Accelerate AI-Driven Monitoring
May 6, 2026 /PRNewswire/ -- Paessler, a leading provider of IT and OT monitoring solutions, today announced the appointment of Mav Turner as Chief Product Officer. This hire deepens Paessler's product leadership as the company continues to invest in innovation that helps IT and OT
More news about: Paessler GmbH - The Monitoring Experts
Apr 27, 2026, 08:45 ET Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
Quantori to deploy a Google Cloud-native, AI-driven peptide design and molecular simulation platform, shortening the cycle from peptide design to D-MAV candidates. The collaboration demonstrates how computational work can accelerate the shift from ligand reengineering to de novo design, which Marschel
More news about: Decoy Therapeutics, Inc
Apr 09, 2026, 08:36 ET Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline
Highly differentiated AI-powered D-MAV discovery platform targeting drugdiscovery in the multi-billion-dollar antiviral marketsCompany to participate in Virtual Investor Closing Bell event to discuss pathforward today at 4:00 PM ET.
More news about: Decoy Therapeutics, Inc
Mar 26, 2026, 09:01 ET Sky Organics Defines 2026 Beauty Trends with USDA Certified Organic Hair, Scalp, and Skincare Innovation
of Sky Organics as we expand beyond castor oil into a broader ecosystem of hair and skincare products," said Mina Kim, Chief Marketing Officer at MAV Beauty Brands.The new products will roll out throughout 2026 across Amazon, Walmart, and Whole Foods Market, as well as online at
More news about: Sky Organics
Mar 26, 2026, 02:23 ET GC Biopharma Receives Marketing Authorization for Varicella Vaccine 'BARYCELA Inj.' in Guatemala
BARYCELA Inj. is a live attenuated vaccine developed using GC Biopharma's proprietary MAV/06 strain. Distinguishing itself from conventional vaccines, BARYCELA Inj. is the world's first varicella vaccine manufactured through an entirely antibiotic-free
More news about: GC Biopharma
Mar 24, 2026, 09:00 ET Zimperium Named Winner of the Coveted Top InfoSec Innovator Awards During RSAC Conference 2026
entry point into enterprise environments. Zimperium's AI-driven Mobile Security Platform, including Mobile Threat Defense (MTD), Mobile App Vetting (MAV), and the Mobile Application Protection Suite (MAPS), delivers comprehensive protection for both mobile devices and the entire mobile application lifecycle.
More news about: Zimperium
Mar 11, 2026, 01:50 ET GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'
analyzed more than 40 studies, including clinical trial results of the MAV/06 vaccine published between 1991 and 2023, post-marketing safety reports, real-world vaccination data, and genomic analysis data.According to the paper, the MAV/06 strain belongs genetically to the same clade (Clade 2) as the
More news about: GC Biopharma
Dec 02, 2025, 00:00 ET GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
this inclusion, BARYCELA Inj. — GC Biopharma's varicella vaccine based on the MAV/06 strain — has attained equivalent international recognition to Oka strain-based vaccines. The WHO also endorsed the interchangeability of MAV/06 and Oka strains, allowing BARYCELA Inj. to be vaccinated with existing varicella
More news about: GC Biopharma